Chimerix INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

7 Nov 2024

CMRX

10-Q: Chimerix Reports Third Quarter 2024 Results, Provides Update on Clinical Programs

Chimerix, Inc. released its third quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

13 Aug 2024

CMRX

Chimerix INC

10-Q: Chimerix Reports Second Quarter 2024 Results; Provides Update on Clinical Programs

Chimerix, Inc. released its second quarter 2024 financial results and provided an update on its clinical development programs, including the ongoing Phase 3 ACTION trial for dordaviprone.

1 May 2024

CMRX

Chimerix INC

10-Q: Chimerix Reports First Quarter 2024 Results; Phase 3 ACTION Study Progresses

Chimerix reports a net loss of $21.9 million for the first quarter of 2024, while its Phase 3 ACTION study for dordaviprone continues to enroll patients.